ONVONTATUG VIDETECAN
UNII 5M9FD5ZCZ7

Substance Identification & Data

This profile provides standardized clinical and technical data for Onvontatug Videtecan, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 5M9FD5ZCZ7.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3061614-65-8 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

5M9FD5ZCZ7

CAS Registry Number

3061614-65-8

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

ONVONTATUG VIDETECAN

Official standardized name for this substance within the FDA UNII nomenclature system.

INN ID

14027

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Onvontatug Videtecan

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Onvontatug Videtecan. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Onvontatug Videtecan

Common Names & Synonyms

H-gamma1 heavy chain (1-448) [VH Musmus/Homsap (Mus musculus IGHV1-20*02 (75.5%) -(IGHD) -IGHJ4*01 (93.3%) S123>T (113)/Homo sapiens IGHV1-2*06 (73.5%) -(IGHD) -IGHJ6*01 (92.9%), CDR-IMGT [8.8.11] (26-33.51-58.97-107)) (1-118) -Homo sapiens IGHG1*01 (100%) G1m17,1 CH1 K120, CH3 D12, L14 (CH1 K120 (215) (119-216), hinge 1-15 (217-231), CH2 (232-341), CH3 D12 (357), L14 (359) (342-446), CHS (447-448)) (119-448)], (221-218')-disulfide with L-kappa light chain (1'-218') [V-KAPPA (Homo sapiens IGKV3D-11*02 (84.0%) -IGKJ4*01 (100%), CDR-IMGT [10.3.9] (27'-36'.54'-56'.93'-101')) (1'-111') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (157'), V101 (195')) (112'-218')]; dimer (227-227'':230-230'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa, substituted at the sulfur atoms of an average of eight L-cysteinyl residues among 221, 227, 230, 218', 221'', 227'', 230'' and 218''' with (3RS)-1-[(30S)-30-{[(2S)-1-{[(2S)-5-(carbamoylamino)-1-{4-[({[(1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl]carbamoyl}oxy)methyl]anilino}-1-oxopentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]carbamoyl}-26,32-dioxo-2,5,8,11,14,17,20,23-octaoxa-27,31-diazatritriacontan-33-yl]-2,5-dioxopyrrolidin-3-yl (videtecan) groups

Immunoglobulin G1, anti-(human folate receptor α) (human-Mus musculus monoclonal BAT6028 γ1-chain), disulfide with human-Mus musculus monoclonal BAT6028 κ-chain, dimer, reduced, thioether with (2S)-2-[[2-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)acetyl]amino]-4-(1-oxo-4,7,10,13,16,19,22,25-octaoxahexacos-1-yl)butanoyl-L-valyl-N5-(aminocarbonyl)-N-[4-[[[[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-1-yl]amino]carbonyl]oxy]methyl]phenyl]-L-ornithinamide

immunoglobulin G1-kappa, anti-[Homo sapiens FOLR1 (folate receptor 1, folate receptor alpha, FR-alpha, adult folate-binding protein, FBP, ovarian tumor-associated antigen MOv18)], monoclonal antibody, conjugated on an average of eight cysteinyl residues to videtecan, comprising a linker and a camptothecin derivative (onvontatug videtecan)

onvontatug videtecan [INN]

External Clinical & Regulatory Resources

Previous UNII5M9F77S8IB

Next UNII5M9FOG2KDI